Myeloma and Related Diseases Registry (MRDR)

Thanks to MRDR participants and contributing sites who provided data for the latest MRDR publication! - 'Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)'. The following link takes you to the paper: doi:10.1038/s41409-021-01308-8

Find out more

This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

What is the registry?

Learn about how the registry works and the data we collect.
Benefits

Participation in the registry provides advantages for sites and patients.
About our projects

Find out about MRDR projects and how registry data is being used.
4926

Patients accrued

3342

Patients with multiple myeloma

55

Number of approved sites

543

Biobank participants

Latest news

MRDR Investigator meeting VIDEO
23 Sep 2021

Missed it? Want another look? Watch the video here!

Read more
Latest MRDR publication!!
29 Jan 2021

New MRDR publication - check it out!!

Read more
10’s all round for FRAIL-M trial!
22 Dec 2020

MRDR-based FRAIL-M trial now has 10 sites & 10 patients recruited!

Read more
APAC MRDR funding for $5.3 million approved
16 Nov 2020

$5.3 million funding over 5 years approved for APAC MRDR

Read more

Participating organisations